GILEAD SCIENCES, INC. Lessee, Operating Lease, Liability, to be Paid, Year One
GILEAD SCIENCES, INC. (GILD) had Lessee, Operating Lease, Liability, to be Paid, Year One of $121.00 million as of 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Commitment and Contingencies › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths · last filed 2026-02-24
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $121.00M.
- 2024-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $132.00M.
- 2023-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $143.00M.
- 2022-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $117.00M.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year One |
|---|---|
| 2025-12-31 | $121.00M 10-K · filed 2026-02-24 |
| 2024-12-31 | $132.00M 10-K · filed 2025-02-28 |
| 2023-12-31 | $143.00M 10-K · filed 2024-02-23 |
| 2022-12-31 | $117.00M 10-K · filed 2023-02-22 |
| 2021-12-31 | $117.00M 10-K · filed 2022-02-23 |
| 2020-12-31 | $127.00M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |